Phosphorylated BLM peptide acts as an agonist for DNA damage response
Nucleic Acids Research · 2025
DOI: 10.1093/nar/gkaf106 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nucleic Acids Research, 2025. Verfasst von Ritu Agrawal und 11 weiteren Autor:innen. Beteiligte Einrichtung: Biotechnology Research and Innovation Council-National Institute of Immunology (BRIC-NII), Aruna Asaf Ali Marg, New Delhi110067, India. Hauptthemen laut MEDLINE: DNA Damage, RecQ Helicases. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Institute of Immunology, National Institute of Biomedical Genomics, Department of Biotechnology, Ministry of Science and Technology, India.
Abstract (Originalsprache)
Upon exposure to ionizing irradiation, the MRE11–RAD50–NBS1 complex potentiates the recruitment of ATM (ataxia-telangiectasia mutated) kinase to the double-strand breaks. We show that the lack of BLM causes a decrease in the autophosphorylation of ATM in mice mammary glands, which have lost one or both copies of BLM. In isogenic human cells, the DNA damage response (DDR) pathway was dampened in the absence of BLM, which negatively affected the recruitment of DDR factors onto the chromatin, thereby indicating a direct role of BLM in augmenting DDR. Mechanistically, this was due to the BLM-dependent dissociation of inactive ATM dimers into active monomers. Fragmentation analysis of BLM followed by kinase assays revealed a 20-mer BLM peptide (91–110 aa), sufficient to enhance ATM-dependent p53 phosphorylation. ATM-mediated phosphorylation of BLM at Thr99 within BLM (91–110) peptide enhanced ATM kinase activity due to its interaction with NBS1 and causing ATM monomerization. Delivery of phosphomimetic T99E counterpart of BLM (91–110 aa) peptide led to ATM activation followed by restoration of the DDR even in the absence of ionizing irradiation (both in cells and in BLM knockout mice), indicating its role as a DDR agonist, which can be potentially used to prevent the initiation of neoplastic transformation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Biotechnology Research and Innovation Council-National Institute of Immunology (BRIC-NII), Aruna Asaf Ali Marg, New Delhi110067, India.
- Biotechnology Research and Innovation Council-National Institute of Biomedical Genomics (BRIC-NIBMG), Kalyani, West Bengal 741251, India.
- Regional Centre for Biotechnology, Faridabad 121001, Haryana, India.
- Valerian Chem Pvt. Ltd, Vproteomics, Green Park, Delhi 110016, India.
ORCID-Profile: Sagar Sengupta
Förderung
- National Institute of Immunology
- National Institute of Biomedical Genomics
- Department of Biotechnology, Ministry of Science and Technology, India
- Board of Research in Nuclear Sciences
- Science and Engineering Research Board
- Council of Scientific and Industrial Research, India
- Indo-French Centre for the Promotion of Advanced Research
- Anusandhan National Research Foundation (ANRF), India
Zitieren
APA
Agrawal, R., Agarwal, H., Mukherjee, C., Chakraborty, B., Sharma, V., Tripathi, V., Kumar, N., Priya, S., Gupta, N., Jhingan, G. D., Bajaj, A., & Sengupta, S. (2025). Phosphorylated BLM peptide acts as an agonist for DNA damage response. Nucleic Acids Research. https://doi.org/10.1093/nar/gkaf106
Vancouver
Agrawal R, Agarwal H, Mukherjee C, Chakraborty B, Sharma V, Tripathi V, et al. Phosphorylated BLM peptide acts as an agonist for DNA damage response. Nucleic Acids Research. 2025. doi:10.1093/nar/gkaf106
BibTeX
@article{Agrawal2025,
author = {Agrawal, Ritu and Agarwal, Himanshi and Mukherjee, Chetana and Chakraborty, Baishali and Sharma, Vandana and Tripathi, Vivek and Kumar, Nitin and Priya, Swati and Gupta, Nidhi and Jhingan, Gagan Deep and Bajaj, Avinash and Sengupta, Sagar},
title = {Phosphorylated BLM peptide acts as an agonist for DNA damage response},
journal = {Nucleic Acids Research},
year = {2025},
doi = {10.1093/nar/gkaf106}
}
EUVIMED